abstract |
The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular relates to a compound of general formula I as multi-targeted receptor tyrosine kinase inhibitors, such as EGFR, Her2, VEGFR and FGFR, and enantiomers, diastereoisomers, racemes and mixtures thereof, or pharmaceutical salt thereof, preparation method thereof, pharmaceutical composition comprising the compound, and the use thereof. |